Results 21 to 30 of about 436,330 (367)

Intraocular infections following biologicals and Janus Kinase inhibitors [PDF]

Indian Journal of Ophthalmology
Parthopratim Dutta Majumder, Rakshita Deepak Kene   +1 more
doaj   +2 more sources

Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases

Drugs, 2023
In recent years, better knowledge of the pathophysiology of inflammatory bowel diseases (IBD) has led to a relevant expansion of the therapeutic arsenal for these conditions. Janus kinase (JAK) inhibitors are a family of small molecules that block one or
P. Núñez, R. Quera, A. Yarur
semanticscholar   +1 more source

Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases

Rheumatology, 2023
Janus kinases (JAKs) are a family of cytosolic tyrosine kinases that regulate cytokine signal transduction, including cytokines involved in a range of inflammatory diseases, such as RA, psoriasis, atopic dermatitis and IBD.
P. Taylor, Ernest Choy, X. Baraliakos, Z. Szekanecz, R. Xavier, J. Isaacs, Sander Strengholt, J. Parmentier, R. Lippe, Yoshiya Tanaka   +9 more
semanticscholar   +1 more source

The Use of Janus Kinase Inhibitors for Lichen Planus: An Evidence-Based Review

Journal of Cutaneous Medicine and Surgery, 2023
Background Lichen Planus (LP) is a dermatological disorder characterized by violaceous papules that affect the cutaneous region, nails, scalp, and mucous membranes.
A. Abduelmula, A. Bagit, A. Mufti, K. Yeung, J. Yeung   +4 more
semanticscholar   +1 more source

In silico method potential therapeutic use of Janus Kinase inhibitors as severe acute respiratory syndrome coronavirus 2 main protease inhibitors

Journal of the Scientific Society, 2023
Background: Coronavirus disease 2019 (COVID-19), it is an infectious respiratory disease caused by SARS corona virus 2 (SARS CoV-2). There are several reports of using JAK (Janus kinase)-inhibitors in persons with COVID-19 and the use of these decreased ...
Shankar Gharge, Sushmita I Hiremath, Akshata S Menasinakai, Mahesh S Palled   +3 more
doaj   +1 more source

Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review

Frontiers in Immunology, 2021
Vitiligo is a multifactorial reversible skin disorder characterized by distinct white patches that result from melanocyte destruction. Activated CXCR3+ CD8+ T cells promote melanocyte detachment and apoptosis through interferon-gamma (IFN-γ secretion and
Fei Qi, Fang Liu, Ling Gao
semanticscholar   +1 more source

Janus kinase inhibitors for alopecia areata: A narrative review.

Indian Journal of Dermatology, Venereology and Leprology, 2023
CThe Janus kinase (JAK) and Signal Transducer and Activator of Transcription (STAT) pathway has been identified as a key player in the pathophysiology of alopecia areata and a potential target for therapy.
R. Haughton, S. Herbert, A. Ji-Xu, L. Downing, S. Raychaudhuri, E. Maverakis   +5 more
semanticscholar   +1 more source

JAK3 as an emerging target for topical treatment of inflammatory skin diseases [PDF]

, 2016
The recent interest and elucidation of the JAK/STAT signaling pathway created new targets for the treatment of inflammatory skin diseases (ISDs). JAK inhibitors in oral and topical formulations have shown beneficial results in psoriasis and alopecia ...
Alves de Medeiros, Ana, De Schepper, Sofie, Desmet, Eline, Lambert, Jo, Speeckaert, Reinhart, Van Gele, Mireille   +5 more
core   +10 more sources

Janus kinase inhibitors in systemic lupus erythematosus: implications for tyrosine kinase 2 inhibition

Frontiers in Medicine, 2023
Aberrant activation of the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway is common in systemic lupus erythematosus (SLE), conferring immune-mediated properties in target tissues.
D. Nikolopoulos, Ioannis Parodis
semanticscholar   +1 more source

Risk of venous thromboembolism with janus kinase inhibitors in inflammatory immune diseases: a systematic review and meta-analysis

Frontiers in Pharmacology, 2023
Objectives: This study aimed to evaluate the risk of venous thrombosis (VTE) associated with Janus kinase (JAK) inhibitors in patients diagnosed with immune-mediated inflammatory diseases. Methods: We conducted a comprehensive search of PUBMED, Cochrane,
Juqian Zhang, Wenhui Li, M. Gong, Yanlun Gu, Hanxu Zhang, B. Dong, Q. Guo, Xiaocong Pang, Q. Xiang, Xu He, Yi-min Cui   +10 more
semanticscholar   +1 more source